Park Medi World Releases Revised Q3 & 9M FY26 Investor Presentation
Park Medi World Limited released a revised investor presentation for Q3 & 9M FY26. Key acquisitions include Febris Multi-Speciality Hospital (₹245 crore) and KP Institute of Medical Sciences. Q3 FY26 revenues reached ₹410 crore with PAT of ₹52.8 crore. 9M FY26 revenues were ₹1,218.9 crore with PAT of ₹196.8 crore.
The release of an updated investor presentation with financial results and details on strategic acquisitions has a moderate impact on stakeholders as it provides crucial information for investment decisions.
The announcement details positive operational performance, strategic acquisitions, and financial growth, indicating a favorable outlook for the company.
Park Medi World Limited has issued a revised Investor Presentation detailing the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025.
The presentation highlights steady operational performance and continued execution of the company's growth strategy during Q3 and 9M FY26. Management commentary indicates healthy revenue growth, supported by stable patient volumes and an improved case mix, with gradual ramp-up across newer and acquired hospitals. Margins remained broadly stable, reflecting ongoing integration and initial gestation of recent capacity additions.
Strategic acquisitions during the period included Febris Multi-Speciality Hospital in New Delhi and KP Institute of Medical Sciences in Agra. The acquisition of KP Institute of Medical Sciences involved an all-cash transaction of approximately ₹245 crore for a 360-bed, NABH-accredited multi-super-speciality hospital, strengthening the company's presence in Uttar Pradesh. Febris Multi-Speciality Hospital, a 200-bed facility in a densely populated catchment area, was acquired through a wholly-owned subsidiary under the IBC process, enhancing access to affordable healthcare in a high-potential urban area and contributing to the goal of reaching 5,260 beds by March 2028.
Financial highlights for Q3 FY26 show revenues of ₹410 crore and EBITDA of ₹99.4 crore, with an EBITDA margin of 24.25%. Profit After Tax (PAT) stood at ₹52.8 crore, with a PAT margin of 12.89% and an Earnings Per Share (EPS) of ₹1.35. For the nine months ended December 31, 2025 (9M FY26), revenues were ₹1,218.9 crore, EBITDA was ₹317.0 crore (EBITDA margin of 26.00%), PAT was ₹196.8 crore (PAT margin of 16.14%), and EPS was ₹5.09.
The company continues its focus on disciplined capital allocation, balance sheet strength, and measured expansion, with immediate priorities including seamless integration of acquired assets, improving asset utilization, and driving sustainable profitability. Medium-term plans involve selectively pursuing growth opportunities while delivering affordable, high-quality healthcare.
What to do with a filing like this
Park Medi World Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Park Medi World Limited. Read the original for the full detail.